Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

coronavirus screening

  • Home
  •  
  • coronavirus screening



  • Most Read
  • Latest Comments
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Spacetalk Leverages AI to Help Wearables PredictHealth Risks
    Spacetalk Leverages AI to Help Wearables PredictHealth Risks
    • News

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • UNITH launches self-service Digital Human Platform ‘interFace’ with strong early traction
    UNITH launches self-service Digital Human Platform ‘interFace’ with strong early traction
    • News

  • City of Calgary engages SenSen for more smart city tech
    City of Calgary engages SenSen for more smart city tech
    • News

  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • News

    MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

    Health tech company MyFiziq (ASX: MYQ) has partnered with Canadian firm NuraLogix which will leverage the two company’s patented imaging technology. Using a smartphone camera, transdermal imaging and artificial intelligence (AI), the newly combined tech aims to determine a user’s probability of having COVID-19, as well as their risk of developing diseases that result in

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.